A court decision points the way to a more even-handed method of dealing with infringement issues in biotechnology patents
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The views expressed in this article belong only to the author and do not reflect the views of any clients of Finnegan, Henderson.
One recent example is reported as Genentech, Inc. v. Wellcome Foundation Ltd., 29 F.3d 1555, 31 U.S.P.Q.2d 1161 (Fed. Cir. 1994).
52 F.3d 967, 34 U.S.P.Q.2d 1321 (Fed. Cir. 1995) (en bane).
Genentech, supra note 2, 14 U.S.P.Q.2d at 1366.
McGill, Inc. v.JohnZink Co., 736 F.2d 666,674 (Fed. Cir.) cert, denied, 469 U.S. 1037 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirschner, M. Bringing Stability to Biotechnology Patents. Nat Biotechnol 13, 1178–1179 (1995). https://doi.org/10.1038/nbt1195-1178
Issue Date:
DOI: https://doi.org/10.1038/nbt1195-1178
